{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:12:41Z","timestamp":1783609961862,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10787-024-01638-1","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T08:26:45Z","timestamp":1736843205000},"page":"593-603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Connecting dots: Preclinical foundations to clinical realities of PDE4 inhibitors in Alzheimer's disease"],"prefix":"10.1007","volume":"33","author":[{"given":"Shilpa","family":"Kumari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Bagri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-0962","authenticated-orcid":false,"given":"Rahul","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"1638_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1767203","author":"DY Abg Abd Wahab","year":"2019","unstructured":"Abg Abd Wahab DY et al (2019) Review on cross talk between neurotransmitters and neuroinflammation in striatum and cerebellum in the mediation of motor behaviour. BioMed Res In. https:\/\/doi.org\/10.1155\/2019\/1767203","journal-title":"BioMed Res In"},{"issue":"1","key":"1638_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/brain\/awq322","volume":"134","author":"M Alam","year":"2011","unstructured":"Alam M, Schwabe K, Krauss JK (2011) The pedunculopontine nucleus area: critical evaluation of interspecies differences relevant for its use as a target for deep brain stimulation. Brain 134(1):11\u201323","journal-title":"Brain"},{"key":"1638_CR3","doi-asserted-by":"crossref","unstructured":"Armstrong P et al. (2024) \u2018Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer\u2019s disease\u2019, Neuropsychopharmacology, pp. 1\u201310","DOI":"10.1038\/s41386-024-01852-z"},{"issue":"1","key":"1638_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.21608\/rpbs.2024.301889.1309","volume":"8","author":"SM Atya","year":"2024","unstructured":"Atya SM (2024) cAMP\/PKA-CREB-BDNF signaling cascade and phosphodiesterase 4 inhibition: a possible neuroprotective approach in Alzheimer\u2019s disease. Records Pharmaceut Biomed Sci 8(1):158\u2013168","journal-title":"Records Pharmaceut Biomed Sci"},{"issue":"3","key":"1638_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2174\/1567205019666220415125447","volume":"19","author":"LB Bergantin","year":"2022","unstructured":"Bergantin LB (2022) A timeline of Ca2+\/cAMP signalling: from basic research to potential therapeutics for dementia. Curr Alzheimer Res 19(3):179\u2013187","journal-title":"Curr Alzheimer Res"},{"key":"1638_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neurobiolaging.2019.01.014","volume":"77","author":"A Blokland","year":"2019","unstructured":"Blokland A et al (2019) Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study. Neurobiol Aging 77:37\u201343","journal-title":"Neurobiol Aging"},{"issue":"8","key":"1638_CR7","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cellsig.2011.03.007","volume":"23","author":"M Breckler","year":"2011","unstructured":"Breckler M et al (2011) Rap-linked cAMP signaling Epac proteins: compartmentation, functioning and disease implications. Cell Signal 23(8):1257\u20131266","journal-title":"Cell Signal"},{"issue":"13","key":"1638_CR8","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.1073\/pnas.1322360111","volume":"111","author":"BC Carlyle","year":"2014","unstructured":"Carlyle BC et al (2014) cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex. Proc Natl Acad Sci 111(13):5036\u20135041","journal-title":"Proc Natl Acad Sci"},{"key":"1638_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2005.07.001","author":"C Chen","year":"2005","unstructured":"Chen C, Bazan NG (2005) Lipid signaling: Sleep, synaptic plasticity, and neuroprotection. Prostaglandins Lipid Mediat. https:\/\/doi.org\/10.1016\/j.prostaglandins.2005.07.001","journal-title":"Prostaglandins Lipid Mediat"},{"key":"1638_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00213-010-1943-3","volume":"212","author":"Y-F Cheng","year":"2010","unstructured":"Cheng Y-F et al (2010) Inhibition of phosphodiesterase-4 reverses memory deficits produced by A\u03b225\u201335 or A\u03b21\u201340 peptide in rats. Psychopharmacology 212:181\u2013191","journal-title":"Psychopharmacology"},{"issue":"1","key":"1638_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1523\/JNEUROSCI.1356-12.2015","volume":"35","author":"CH Choi","year":"2015","unstructured":"Choi CH et al (2015) PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome. J Neurosci 35(1):396\u2013408","journal-title":"J Neurosci"},{"issue":"6","key":"1638_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.neuint.2011.08.012","volume":"59","author":"SH Christiansen","year":"2011","unstructured":"Christiansen SH et al (2011) Combined anti-inflammatory effects of \u03b22-adrenergic agonists and PDE4 inhibitors on astrocytes by upregulation of intracellular cAMP. Neurochem Int 59(6):837\u2013846","journal-title":"Neurochem Int"},{"issue":"9","key":"1638_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/ijnp\/pyad042","volume":"26","author":"Y-F Cong","year":"2023","unstructured":"Cong Y-F et al (2023) Rolipram ameliorates memory deficits and depression-like behavior in APP\/PS1\/tau triple transgenic mice: involvement of neuroinflammation and apoptosis via cAMP signaling. Int J Neuropsychopharmacol 26(9):585\u2013598","journal-title":"Int J Neuropsychopharmacol"},{"issue":"15","key":"1638_CR14","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.3390\/molecules27154964","volume":"27","author":"L Crocetti","year":"2022","unstructured":"Crocetti L et al (2022) An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022. Molecules 27(15):4964","journal-title":"Molecules"},{"issue":"5","key":"1638_CR15","first-page":"364","volume":"8","author":"SG Dastidar","year":"2007","unstructured":"Dastidar SG, Rajagopal D, Ray A (2007) Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 8(5):364","journal-title":"Curr Opin Investig Drugs"},{"issue":"1","key":"1638_CR16","doi-asserted-by":"publisher","first-page":"19737","DOI":"10.1038\/s41598-021-98743-w","volume":"11","author":"X-L Dong","year":"2021","unstructured":"Dong X-L et al (2021) The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP\/AMPK\/SIRT1 pathway. Sci Rep 11(1):19737","journal-title":"Sci Rep"},{"key":"1638_CR17","doi-asserted-by":"publisher","first-page":"1407871","DOI":"10.3389\/fphar.2024.1407871","volume":"15","author":"T Fan","year":"2024","unstructured":"Fan T et al (2024) PDE4 inhibitors: potential protective effects in inflammation and vascular diseases. Front Pharmacol 15:1407871","journal-title":"Front Pharmacol"},{"key":"1638_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11011-018-0374-4","volume":"34","author":"H Feng","year":"2019","unstructured":"Feng H et al (2019) Roflumilast ameliorates cognitive impairment in APP\/PS1 mice via cAMP\/CREB\/BDNF signaling and anti-neuroinflammatory effects. Metab Brain Dis 34:583\u2013591","journal-title":"Metab Brain Dis"},{"issue":"1","key":"1638_CR19","first-page":"8","volume":"5","author":"BA Fertig","year":"2018","unstructured":"Fertig BA, Baillie GS (2018) PDE4-mediated cAMP signalling. J Cardiovas Dev Dis 5(1):8","journal-title":"J Cardiovas Dev Dis"},{"key":"1638_CR20","doi-asserted-by":"crossref","unstructured":"Fusco FR, Paldino E (2017) Promising Candidates for Drug Repurposing in Huntington\u2019s Disease, in Drug Repositioning. CRC Press, pp. 221\u2013240","DOI":"10.4324\/9781315373669-12"},{"key":"1638_CR21","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00213-018-5134-y","volume":"238","author":"J Gilleen","year":"2021","unstructured":"Gilleen J et al (2021) An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients. Psychopharmacology 238:1279\u20131289","journal-title":"Psychopharmacology"},{"key":"1638_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109927","volume":"117","author":"AA Gomaa","year":"2023","unstructured":"Gomaa AA et al (2023) Intermittent treatment with Apremilast, a phosphodiesterase-4 inhibitor, ameliorates Alzheimer\u2019s-like pathology and symptoms through multiple targeting actions in aged T2D rats. Int Immunopharmacol 117:109927","journal-title":"Int Immunopharmacol"},{"key":"1638_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3389\/fncel.2019.00357","volume":"13","author":"J Gon\u00e7alves-Ribeiro","year":"2019","unstructured":"Gon\u00e7alves-Ribeiro J et al (2019) Glutamate transporters in hippocampal LTD\/LTP: not just prevention of excitotoxicity. Front Cell Neurosci 13:357","journal-title":"Front Cell Neurosci"},{"issue":"22","key":"1638_CR24","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1002\/1873-3468.14467","volume":"596","author":"R Gopalakrishna","year":"2022","unstructured":"Gopalakrishna R et al (2022) cAMP-induced decrease in cell-surface laminin receptor and cellular prion protein attenuates amyloid-\u03b2 uptake and amyloid-\u03b2-induced neuronal cell death. FEBS Lett 596(22):2914\u20132927","journal-title":"FEBS Lett"},{"issue":"2","key":"1638_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1476-5381.2009.00458.x","volume":"159","author":"M Grandoch","year":"2010","unstructured":"Grandoch M, Roscioni SS, Schmidt M (2010) The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br J Pharmacol 159(2):265\u2013284","journal-title":"Br J Pharmacol"},{"key":"1638_CR26","doi-asserted-by":"crossref","unstructured":"Hansen RT, Zhang HT (2017) \u2018The past, present, and future of phosphodiesterase-4 modulation for age-induced memory loss\u2019, Phosphodiesterases: CNS Funct Dis pp. 169\u2013199","DOI":"10.1007\/978-3-319-58811-7_7"},{"issue":"3","key":"1638_CR27","first-page":"291","volume":"21","author":"T Hansen","year":"2015","unstructured":"Hansen T, Zhang R (2015) Phosphodiesterase-4 modulation as a potential therapeutic for cognitive loss in pathological and non-pathological aging: possibilities and pitfalls. Curr Pharmaceut Design 21(3):291\u2013302","journal-title":"Curr Pharmaceut Design"},{"issue":"1","key":"1638_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1124\/jpet.116.237388","volume":"360","author":"A Harada","year":"2017","unstructured":"Harada A, Suzuki K, Kimura H (2017) TAK-063, a novel phosphodiesterase 10A inhibitor, protects from striatal neurodegeneration and ameliorates behavioral deficits in the R6\/2 mouse model of Huntington\u2019s disease. J Pharmacol Exp Ther 360(1):75\u201383","journal-title":"J Pharmacol Exp Ther"},{"issue":"6083","key":"1638_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1126\/science.1215327","volume":"336","author":"SA Hawley","year":"2012","unstructured":"Hawley SA et al (2012) The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336(6083):918\u2013922","journal-title":"Science"},{"key":"1638_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105816","volume":"172","author":"S-X Jin","year":"2022","unstructured":"Jin S-X et al (2022) A\u03b2 oligomers from human brain impair mossy fiber LTP in CA3 of hippocampus, but activating cAMP-PKA and cGMP-PKG prevents this. Neurobiol Dis 172:105816","journal-title":"Neurobiol Dis"},{"key":"1638_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejphar.2018.05.015","volume":"832","author":"M Kaundal","year":"2018","unstructured":"Kaundal M et al (2018) Betulinic acid, a natural PDE inhibitor restores hippocampal cAMP\/cGMP and BDNF, improve cerebral blood flow and recover memory deficits in permanent BCCAO induced vascular dementia in rats. Eur J Pharmacol 832:56\u201366","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"1638_CR32","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.biopsych.2021.10.012","volume":"91","author":"W Koh","year":"2022","unstructured":"Koh W et al (2022) Astrocytes render memory flexible by releasing D-serine and regulating NMDA receptor tone in the hippocampus. Biol Psychiat 91(8):740\u2013752","journal-title":"Biol Psychiat"},{"key":"1638_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173877","volume":"895","author":"S Kumari","year":"2021","unstructured":"Kumari S, Deshmukh R (2021) \u03b2-lactam antibiotics to tame down molecular pathways of Alzheimer\u2019s disease. Eur J Pharmacol 895:173877","journal-title":"Eur J Pharmacol"},{"key":"1638_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/alz.067689","volume":"18","author":"S Kumari","year":"2022","unstructured":"Kumari S, Agrawal M, Deshmukh RR (2022) Fingolimod (FTY720) offers neuroprotection against AlCl3 induced experimental dementia in rats. Alzheimer\u2019s Dementia 18:e067689","journal-title":"Alzheimer\u2019s Dementia"},{"key":"1638_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.576723","volume":"12","author":"SN Leslie","year":"2020","unstructured":"Leslie SN et al (2020) Phosphodiesterase PDE4D is decreased in frontal cortex of aged rats and positively correlated with working memory performance and inversely correlated with PKA phosphorylation of tau. Front Aging Neurosci 12:576723","journal-title":"Front Aging Neurosci"},{"key":"1638_CR36","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.physbeh.2014.12.001","volume":"139","author":"Q-Q Li","year":"2015","unstructured":"Li Q-Q et al (2015) Hippocampal cAMP\/PKA\/CREB is required for neuroprotective effect of acupuncture. Physiol Behav 139:482\u2013490","journal-title":"Physiol Behav"},{"issue":"1","key":"1638_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1574885511666160421145339","volume":"11","author":"C-H Lin","year":"2016","unstructured":"Lin C-H, Chang S-H, Fang J-Y (2016) Recent advances using phosphodiesterase 4 (PDE4) inhibitors to treat inflammatory disorders: animal and clinical studies. Curr Drug Therapy 11(1):21\u201340","journal-title":"Curr Drug Therapy"},{"issue":"3","key":"1638_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/13543776.2022.2026328","volume":"32","author":"Z Liu","year":"2022","unstructured":"Liu Z et al (2022) Phosphodiesterase-4 inhibitors: a review of current developments (2013\u20132021). Expert Opin Ther Pat 32(3):261\u2013278","journal-title":"Expert Opin Ther Pat"},{"issue":"18","key":"1638_CR39","doi-asserted-by":"publisher","first-page":"10616","DOI":"10.3390\/ijms231810616","volume":"23","author":"C Lugnier","year":"2022","unstructured":"Lugnier C (2022) The complexity and multiplicity of the specific cAMP phosphodiesterase family: PDE4, open new adapted therapeutic approaches. Int J Mol Sci 23(18):10616","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1638_CR40","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/nm.3951","volume":"21","author":"SW Min","year":"2015","unstructured":"Min SW et al (2015) \u2018Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 21(10):1154\u20131162. https:\/\/doi.org\/10.1038\/nm.3951","journal-title":"Nat Med"},{"issue":"3","key":"1638_CR41","doi-asserted-by":"publisher","first-page":"C508","DOI":"10.1152\/ajpcell.00373.2001","volume":"282","author":"KS Murthy","year":"2002","unstructured":"Murthy KS, Zhou H, Makhlouf GM (2002) PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V\/VI in smooth muscle. Am J Physiol Cell Physiol 282(3):C508\u2013C517","journal-title":"Am J Physiol Cell Physiol"},{"key":"1638_CR42","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1007\/s11064-021-03327-9","volume":"46","author":"S Nazir","year":"2021","unstructured":"Nazir S et al (2021) Drotaverine inhibitor of PDE4: Reverses the streptozotocin induced alzheimer\u2019s disease in mice. Neurochem Res 46:1814\u20131829","journal-title":"Neurochem Res"},{"issue":"1","key":"1638_CR43","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s11033-024-09484-8","volume":"51","author":"PD Nongthombam","year":"2024","unstructured":"Nongthombam PD, Haobam R (2024) Targeting phosphodiesterase 4 as a potential therapy for Parkinson\u2019s disease: a review. Mol Biol Rep 51(1):510","journal-title":"Mol Biol Rep"},{"issue":"3","key":"1638_CR44","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/brain\/awac136","volume":"146","author":"G Oliveros","year":"2023","unstructured":"Oliveros G et al (2023) Repurposing ibudilast to mitigate Alzheimer\u2019s disease by targeting inflammation. Brain 146(3):898\u2013911","journal-title":"Brain"},{"key":"1638_CR45","unstructured":"Padda IS, Parmar M (2021) \u2018Aducanumab\u2019, in StatPearls [Internet]. StatPearls Publishing"},{"issue":"3","key":"1638_CR46","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1124\/pharmrev.120.000273","volume":"73","author":"D Paes","year":"2021","unstructured":"Paes D et al (2021) The molecular biology of phosphodiesterase 4 enzymes as pharmacological targets: an interplay of isoforms, conformational states, and inhibitors. Pharmacol Rev 73(3):1016\u20131049","journal-title":"Pharmacol Rev"},{"issue":"7","key":"1638_CR47","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00018-023-04804-w","volume":"80","author":"D Paes","year":"2023","unstructured":"Paes D et al (2023) Ablation of specific long PDE4D isoforms increases neurite elongation and conveys protection against amyloid-\u03b2 pathology. Cell Mol Life Sci 80(7):178","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"1638_CR48","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/glia.22986","volume":"64","author":"DD Pearse","year":"2016","unstructured":"Pearse DD, Hughes ZA (2016) PDE4B as a microglia target to reduce neuroinflammation. Glia 64(10):1698\u20131709","journal-title":"Glia"},{"issue":"2","key":"1638_CR49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O et al (2019) Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med 25(2):277\u2013283. https:\/\/doi.org\/10.1038\/s41591-018-0304-3","journal-title":"Nat Med"},{"issue":"1","key":"1638_CR50","doi-asserted-by":"publisher","first-page":"46320","DOI":"10.1038\/srep46320","volume":"7","author":"R Ricciarelli","year":"2017","unstructured":"Ricciarelli R et al (2017) Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer\u2019s disease. Sci Rep 7(1):46320","journal-title":"Sci Rep"},{"issue":"1","key":"1638_CR51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/ADR-200191","volume":"4","author":"O Sanders","year":"2020","unstructured":"Sanders O, Rajagopal L (2020) Phosphodiesterase inhibitors for Alzheimer\u2019s disease: a systematic review of clinical trials and epidemiology with a mechanistic rationale. J Alzheimer\u2019s Dis Rep 4(1):185\u2013215","journal-title":"J Alzheimer\u2019s Dis Rep"},{"issue":"3","key":"1638_CR52","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2174\/1570159X17666191010103044","volume":"18","author":"R Schreiber","year":"2020","unstructured":"Schreiber R, Hollands R, Blokland A (2020) A mechanistic rationale for PDE-4 inhibitors to treat residual cognitive deficits in acquired brain injury. Curr Neuropharmacol 18(3):188\u2013201","journal-title":"Curr Neuropharmacol"},{"issue":"13","key":"1638_CR53","first-page":"1371","volume":"21","author":"VK Sharma","year":"2020","unstructured":"Sharma VK, Singh TG, Singh S (2020) Cyclic nucleotides signaling and phosphodiesterase inhibition: defying Alzheimer\u2019s disease. Curr Drug Targets 21(13):1371\u20131384","journal-title":"Curr Drug Targets"},{"key":"1638_CR54","doi-asserted-by":"crossref","unstructured":"Sheng J et al (2022) \u2018Inhibition of phosphodiesterase: a novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer\u2019s\u2019","DOI":"10.3389\/fnagi.2022.1019187"},{"key":"1638_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.794458","volume":"12","author":"J Shi","year":"2021","unstructured":"Shi J et al (2021a) Baicalein ameliorates a\u03b2-induced memory deficits and neuronal atrophy via inhibition of PDE2 and PDE4. Front Pharmacol 12:794458","journal-title":"Front Pharmacol"},{"key":"1638_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.722580","volume":"13","author":"Y Shi","year":"2021","unstructured":"Shi Y et al (2021b) Phosphodiesterase-4D knockdown in the prefrontal cortex alleviates memory deficits and synaptic failure in mouse model of Alzheimer\u2019s disease. Front Aging Neurosci 13:722580","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"1638_CR57","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1042\/BST20190763","volume":"47","author":"AJ Tibbo","year":"2019","unstructured":"Tibbo AJ, Tejeda GS, Baillie GS (2019) Understanding PDE4\u2019s function in Alzheimer\u2019s disease; a target for novel therapeutic approaches. Biochem Soc Trans 47(5):1557\u20131565","journal-title":"Biochem Soc Trans"},{"key":"1638_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbr.2016.01.031","volume":"303","author":"T Vanmierlo","year":"2016","unstructured":"Vanmierlo T et al (2016) The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses. Behav Brain Res 303:26\u201333. https:\/\/doi.org\/10.1016\/j.bbr.2016.01.031","journal-title":"Behav Brain Res"},{"key":"1638_CR59","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51705","author":"B Vejandla","year":"2024","unstructured":"Vejandla B et al (2024) Alzheimer\u2019s disease: The past, present, and future of a globally progressive disease. Cureus. https:\/\/doi.org\/10.7759\/cureus.51705","journal-title":"Cureus"},{"issue":"20","key":"1638_CR60","doi-asserted-by":"publisher","first-page":"13217","DOI":"10.1073\/pnas.172504199","volume":"99","author":"OV Vitolo","year":"2002","unstructured":"Vitolo OV et al (2002) Amyloid \u03b2-peptide inhibition of the PKA\/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci 99(20):13217\u201313221","journal-title":"Proc Natl Acad Sci"},{"issue":"10","key":"1638_CR61","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.neurobiolaging.2007.12.004","volume":"30","author":"Q Wang","year":"2009","unstructured":"Wang Q, Rowan MJ, Anwyl R (2009) Inhibition of LTP by beta-amyloid is prevented by activation of \u03b22 adrenoceptors and stimulation of the cAMP\/PKA signalling pathway. Neurobiol Aging 30(10):1608\u20131613","journal-title":"Neurobiol Aging"},{"issue":"6","key":"1638_CR62","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1017\/S1461145711000836","volume":"15","author":"C Wang","year":"2012","unstructured":"Wang C et al (2012) The phosphodiesterase-4 inhibitor rolipram reverses A\u03b2-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats. Int J Neuropsychopharmacol 15(6):749\u2013766","journal-title":"Int J Neuropsychopharmacol"},{"issue":"15","key":"1638_CR63","doi-asserted-by":"publisher","first-page":"10298","DOI":"10.1074\/jbc.M112.415141","volume":"288","author":"D Wang","year":"2013","unstructured":"Wang D et al (2013) \u03b22 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models. J Biol Chem 288(15):10298\u201310307","journal-title":"J Biol Chem"},{"issue":"14","key":"1638_CR64","doi-asserted-by":"publisher","first-page":"17380","DOI":"10.18632\/oncotarget.8041","volume":"7","author":"G Wang","year":"2016","unstructured":"Wang G et al (2016) The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling. Oncotarget 7(14):17380","journal-title":"Oncotarget"},{"issue":"10","key":"1638_CR65","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/ijnp\/pyaa048","volume":"23","author":"H Wang","year":"2020","unstructured":"Wang H et al (2020) The phosphodiesterase-4 inhibitor roflumilast, a potential treatment for the comorbidity of memory loss and depression in Alzheimer\u2019s disease: a preclinical study in APP\/PS1 transgenic mice. Int J Neuropsychopharmacol 23(10):700\u2013711","journal-title":"Int J Neuropsychopharmacol"},{"key":"1638_CR66","doi-asserted-by":"publisher","DOI":"10.1080\/13607863.2022.2032601","author":"KE Watts","year":"2022","unstructured":"Watts KE et al (2022) (2022) Systematic review of pharmacological interventions for people with Lewy body dementia. Aging Mental Health. https:\/\/doi.org\/10.1080\/13607863.2022.2032601","journal-title":"Aging Mental Health"},{"issue":"3","key":"1638_CR67","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1038\/tp.2012.17","volume":"2","author":"V Wiescholleck","year":"2012","unstructured":"Wiescholleck V, Manahan-Vaughan D (2012) PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis. Transl Psychiatry 2(3):e89\u2013e89","journal-title":"Transl Psychiatry"},{"key":"1638_CR68","unstructured":"Zeitler S (2020) Interaction of the Acid Sphingomyelinase\/Ceramide System and TRPC6 Ion Channels in neuronal cells. Friedrich-Alexander-Universitaet Erlangen-Nuernberg (Germany)"},{"issue":"2","key":"1638_CR69","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3233\/JAD-122236","volume":"38","author":"C Zhang","year":"2014","unstructured":"Zhang C et al (2014) RNA Interference-Mediated Knockdown of Long-Form Phosphodiesterase-4D (PDE4D) Enzyme Reverses Amyloid-\u03b2 42-Induced Memory Deficits in Mice. J Alzheimer\u2019s Dis 38(2):269\u2013280","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1638_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2023.114798","volume":"459","author":"H Zhao","year":"2024","unstructured":"Zhao H et al (2024) Treatment with the selective PDE4B inhibitor A-33 or PDE4D inhibitor zatolmilast prevents sleep deprivation-induced deficits in spatial pattern separation. Behav Brain Res 459:114798","journal-title":"Behav Brain Res"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01638-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-024-01638-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01638-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:40:25Z","timestamp":1740109225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-024-01638-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1638"],"URL":"https:\/\/doi.org\/10.1007\/s10787-024-01638-1","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}